Ascletis' ASC22 Shows Potential Of Functional Cure Of Chronic Hepatitis B In Phase IIb Trial

Ascletis Pharma Inc. presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for functional cure of chronic hepatitis B at oral session of EASL ILC 2022 on June 25, 2022, Beijing Time.

The Phase IIb clinical trial results further demonstrated the potential of ASC22+nucleos(t)ide analogs treatment as a functional cure for chronic hepatitis B.

The interim report is based on a randomized, single-blind, multi-center Phase IIb clinical trial to assess the efficacy and safety of ASC22 in treatment of chronic hepatitis B or CHB patients.

In 1.0 mg/kg ASC22 cohort, 75 CHB patients were randomized to be treated with 1.0 mg/kg ASC22 (n=60) or placebo (PBO, n=15) once every 2 weeks plus nucleos(t)ide analogs (NAs) for 24-week and then followed for another 24 weeks.

According to the Phase IIb clinical study results, 42.9% patients with baseline HBsAg =100 IU/mL (n=7) obtained sustained HBsAg loss. ALT flares were observed on 21% patients in ASC22 group (n=48) while none in PBO group.

Patients with ALT flares had more HBsAg reduction. Among the three patients with sustained HBsAg loss, two experienced ALT flares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing company Lyft announced its foray into the media and advertisement business with the launch of Lyft Media as part of its vision to build the world's largest transportation media network. Lyft Media has built a suite of new products to allow advertisers to engage with Lyft's growing audience throughout their transportation journeys. Sysco Corp. (SYY) Tuesday reported a more than a three-times surge in fourth-quarter earnings, supported by 17.5 percent growth in sales. The company projects fiscal 2023 adjusted earnings to grow. Earnings for the quarter spiked to $509.99 million from $151.09 million last year. On a per share basis,... Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22.
Follow RTT